X

Trial Profile

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 21 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalteparin sodium (Primary) ; Dalteparin sodium (Primary) ; Enoxaparin sodium (Primary) ; Enoxaparin sodium (Primary) ; Nafamostat (Primary) ; Tinzaparin sodium (Primary) ; Tinzaparin sodium (Primary) ; Aspirin; COVID-2019 hyperimmune globulin
Indications COVID 2019 infections; Thrombosis
Focus Therapeutic Use
Acronyms ASCOT ADAPT

Most Recent Events

12 May 2024 Planned number of patients changed from 2500 to 2200.
12 May 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
12 May 2024 Planned primary completion date changed from 31 Dec 2024 to 25 Jul 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com